Top 5 Stocks to Buy Now
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free CLBX Stock Alerts

Cellbxhealth (CLBX) Competitors

GBX 1.51 +0.11 (+7.93%)
As of 11:53 AM Eastern
Compare

CLBX vs. TILS, VSN, BVXP, MPH, and FARN

Should you buy Cellbxhealth stock or one of its competitors? MarketBeat compares Cellbxhealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellbxhealth include Tiziana Life Sciences (TILS), Verseon (VSN), Bioventix (BVXP), Mereo BioPharma Group plc (MPH.L) (MPH), and Faron Pharmaceuticals Oy (FARN). These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Cellbxhealth (LON:CLBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

1.0% of Cellbxhealth shares are owned by institutional investors. 1.0% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Cellbxhealth N/A N/A N/A

In the previous week, Cellbxhealth had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for Cellbxhealth and 0 mentions for Tiziana Life Sciences. Cellbxhealth's average media sentiment score of 1.38 beat Tiziana Life Sciences' score of 0.71 indicating that Cellbxhealth is being referred to more favorably in the news media.

Company Overall Sentiment
Tiziana Life Sciences Positive
Cellbxhealth Positive

Cellbxhealth is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Cellbxhealth£2.62M11.21N/A-£4.80N/A

Summary

Cellbxhealth beats Tiziana Life Sciences on 7 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Verseon?

Cellbxhealth (LON:CLBX) and Verseon (LON:VSN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Verseon N/A N/A N/A

1.0% of Cellbxhealth shares are owned by institutional investors. 1.0% of Cellbxhealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cellbxhealth had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Cellbxhealth and 0 mentions for Verseon. Cellbxhealth's average media sentiment score of 1.38 beat Verseon's score of 0.00 indicating that Cellbxhealth is being referred to more favorably in the media.

Company Overall Sentiment
Cellbxhealth Positive
Verseon Neutral

Cellbxhealth is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£2.62M11.21N/A-£4.80N/A
VerseonN/AN/AN/A-£14.30N/A

Summary

Cellbxhealth beats Verseon on 7 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Bioventix?

Cellbxhealth (LON:CLBX) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Bioventix has higher revenue and earnings than Cellbxhealth. Cellbxhealth is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£2.62M11.21N/A-£4.80N/A
Bioventix£12.54M7.50£8.12M£140.5212.81

Bioventix has a net margin of 59.30% compared to Cellbxhealth's net margin of 0.00%. Bioventix's return on equity of 65.83% beat Cellbxhealth's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Bioventix 59.30%65.83%54.07%

In the previous week, Cellbxhealth and Cellbxhealth both had 1 articles in the media. Cellbxhealth's average media sentiment score of 1.38 beat Bioventix's score of 0.00 indicating that Cellbxhealth is being referred to more favorably in the media.

Company Overall Sentiment
Cellbxhealth Positive
Bioventix Neutral

1.0% of Cellbxhealth shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 1.0% of Cellbxhealth shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Bioventix beats Cellbxhealth on 8 of the 10 factors compared between the two stocks.

How does Cellbxhealth compare to Mereo BioPharma Group plc (MPH.L)?

Cellbxhealth (LON:CLBX) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

In the previous week, Cellbxhealth had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for Cellbxhealth and 0 mentions for Mereo BioPharma Group plc (MPH.L). Cellbxhealth's average media sentiment score of 1.38 beat Mereo BioPharma Group plc (MPH.L)'s score of 0.00 indicating that Cellbxhealth is being referred to more favorably in the media.

Company Overall Sentiment
Cellbxhealth Positive
Mereo BioPharma Group plc (MPH.L) Neutral

1.0% of Cellbxhealth shares are owned by institutional investors. 1.0% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cellbxhealth is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£2.62M11.21N/A-£4.80N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

Summary

Cellbxhealth beats Mereo BioPharma Group plc (MPH.L) on 6 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Faron Pharmaceuticals Oy?

Cellbxhealth (LON:CLBX) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Cellbxhealth had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 1 mentions for Cellbxhealth and 0 mentions for Faron Pharmaceuticals Oy. Cellbxhealth's average media sentiment score of 1.38 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that Cellbxhealth is being referred to more favorably in the media.

Company Overall Sentiment
Cellbxhealth Positive
Faron Pharmaceuticals Oy Neutral

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Cellbxhealth's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

1.0% of Cellbxhealth shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 1.0% of Cellbxhealth shares are owned by company insiders. Comparatively, 2.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cellbxhealth has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£2.62M11.21N/A-£4.80N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

Summary

Cellbxhealth beats Faron Pharmaceuticals Oy on 6 of the 9 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLBX vs. The Competition

Export
MetricCellbxhealthBiotechnology IndustryMedical SectorLON Exchange
Market Cap£29.42M£469.50M£6.49B£2.78B
Dividend YieldN/A3.86%2.68%6.16%
P/E Ratio-0.313.1824.68365.72
Price / Sales11.216,492.91530.1586,253.73
Price / CashN/A13.1327.9227.85
Price / BookN/A91.5110.877.93
Net IncomeN/A-£96.07M£3.56B£5.89B
7 Day PerformanceN/A1.88%1.99%-0.87%
1 Month PerformanceN/A0.96%0.74%-0.76%
1 Year PerformanceN/A65.10%33.47%70.67%

Cellbxhealth Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 1.51
+7.9%		N/AN/A£29.42M£2.62MN/AN/A
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
BVXP
Bioventix
N/AGBX 1,750
+0.3%		N/A-28.8%£91.44M£12.54M12.4512
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CLBX) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel